SCHEMBL15919479

SCHEMBL15919479

CC(C)(C)OC(=O)NNC(=O)c1cc(-c2ccc(C#Cc3ccc(OCC(NC(=O)OC(C)(C)C)C(=O)O)cc3)cc2)nc2ccncc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ ALOX12 P18054 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ KLF5 Q13887 1/20 0.41
▸ ACACB O00763 4/20 0.41
▸ ACACA Q13085 3/20 0.41
▸ LMNA P02545 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15919481 0.94 TACR3 (0.40) RAB9AKDM4ENPC1KMT2AALDH1A1
SCHEMBL15919548 0.85 ACACB (0.43) RAB9AKDM4ENPC1KMT2AALDH1A1
SCHEMBL15919475 0.83 EGLN2 (0.38) RAB9AKDM4ENPC1KMT2AALDH1A1
SCHEMBL15919517 0.82 ACACB (0.44) RAB9AKDM4ENPC1KMT2AALDH1A1
SCHEMBL15919518 0.82 KMT2A (0.46) KDM4ENPC1KMT2AALDH1A1MEN1
SCHEMBL15919729 0.82 ACACB (0.35) RAB9AKDM4ENPC1KMT2AALDH1A1
SCHEMBL15904908 0.81 ACACB (0.46) RAB9AKDM4ENPC1KMT2AALDH1A1
SCHEMBL15919549 0.81 ACACB (0.42) KDM4EKMT2AALDH1A1MEN1NFKB1
SCHEMBL15919281 0.80 ACACB (0.41) KDM4ENPC1KMT2AALDH1A1MEN1
SCHEMBL15919476 0.79 ACACB (0.37) KMT2AMEN1ACACBACACAEGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 — — US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 — — US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 — — US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 — — US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO RAB9A 2721/4885KDM4E 3322/4885NPC1 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback